JZYY(SH:600750)2018-04-26 16:00Financial Performance - Net profit attributable to shareholders rose by 6.25% to CNY 116,030,217.44 year-on-year[5] - Operating revenue grew by 7.27% to CNY 460,332,636.77 compared to the same period last year[5] - Total operating revenue for Q1 2018 was CNY 460,332,636.77, an increase of 7.6% compared to CNY 429,130,889.71 in the same period last year[29] - Net profit for Q1 2018 reached CNY 116,066,821.85, representing a 6.5% increase from CNY 109,206,928.46 in Q1 2017[30] - The overall comprehensive income for Q1 2018 was approximately 101.42 million RMB, slightly lower than 101.48 million RMB in the previous period[34] Asset and Liability Management - Total assets increased by 2.39% to CNY 3,444,638,571.12 compared to the end of the previous year[5] - The total liabilities were 413,208,018.67 RMB, down from 448,738,398.80 RMB at the beginning of the year[23] - Accounts receivable at the end of the period amounted to 21,530,232.56 RMB, an increase of 546,000 RMB, representing a growth of 34% compared to the end of the previous year[16] - Other receivables at the end of the period totaled 10,921,727.73 RMB, up by 283,000 RMB, reflecting a growth of 34.94% year-on-year, mainly due to increased employee advances[16] - Other non-current assets reached 25,665,746.27 RMB, an increase of 1,350,000 RMB, showing a growth of 110.97%, attributed to increased external entrusted loans[16] - The balance of employee compensation payable at the end of the period was 26,731,462.36 RMB, a decrease of 3,629,000 RMB, representing a decline of 57.58% due to the payment of last year's accrued annual performance bonuses[16] - The balance of taxes payable at the end of the period was 65,401,148.29 RMB, an increase of 2,066,000 RMB, reflecting a growth of 46.19% due to increased unremitted VAT and corporate income tax[16] - Other current liabilities increased to 23,544,703.40 RMB, up by 1,679,000 RMB, representing a growth of 248.47% due to increased unrecognized expenses[17] Cash Flow Analysis - The net cash flow from operating activities was CNY 106,155,123.61, a significant improvement from a loss of CNY 13,686,917.26 in the previous year[5] - The net cash flow from operating activities for the period was 10,616,000 RMB, an increase of 11,984,000 RMB compared to the same period last year, primarily due to an increase in bank acceptance bill collections[17] - The net cash flow from investing activities was -5,265,000 RMB, a decrease of 2,924,000 RMB year-on-year, mainly due to increased investment in engineering equipment and entrusted loans[17] - Cash flow from operating activities generated a net inflow of approximately 106.16 million RMB, a significant improvement from a net outflow of 13.69 million RMB in the previous period[37] - Investment activities resulted in a net cash outflow of approximately 52.62 million RMB, compared to a net outflow of 22.16 million RMB in the previous period, indicating increased investment activity[41] - The company received approximately 20 million RMB from financing activities, but had a net cash outflow of approximately 70.90 million RMB due to debt repayments and other financing costs[38] Revenue Breakdown - Revenue from the non-prescription drug category increased by 8.61% to CNY 401,808,977.63[10] - Revenue from the liquor segment surged by 96.12% to CNY 1,974,704.26[10] - Revenue from the East China region increased by 17.83% to CNY 122,194,729.67[13] - Total revenue for Q1 2018 was approximately 119.77 million RMB, showing a slight increase compared to 119.57 million RMB in the previous period[34] - Cash received from sales of goods and services was approximately 495.31 million RMB, up from 258.32 million RMB in the previous period, reflecting strong sales growth[36] Market Strategy - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[30] - The company plans to continue focusing on expanding its market presence and investing in new product development[34] Shareholder Information - The total number of shareholders reached 31,108 as of the report date[15] Performance Ratios - The weighted average return on equity decreased by 0.19 percentage points to 3.90%[5] - The gross profit margin for the pharmaceutical industry segment decreased by 0.81 percentage points to 67.70%[10] - The company reported a gross profit margin of approximately 28.9% for Q1 2018, compared to 31.5% in Q1 2017[30] - Earnings per share for Q1 2018 were CNY 0.39, compared to CNY 0.36 in the same quarter last year[31] - The basic earnings per share for Q1 2018 remained stable, with no specific figures provided in the report[34]